Update on the Cardiac Safety of Moxifloxacin [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] clinical trials and postmarketing studies. Clin Ther 2004; 26: 940- 50. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT- interval prolongation. Drug Saf 2008; 31: 67-77. Hulhoven R, Rosillon D, Letiexhe M, et al. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 2007; 63: 1011-17. Stylianou A, Roger J, Stephens K. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies. J Biopharm Stat 2008; 18: 502-16. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008; 84: 475-80. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocard 2004; 37(Suppl): 81-90. Kang J, Wang L, Chen X-L, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122-6. U.S. Food and Drug Administration. International Conference on Harmonization (ICH). E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs [Internet]. Current Step 4 version dated 12 May 2005. Available from: http://www.fda.gov/RegulatoryInformation/Guidan ces/ucm129335.htm Vos MA. Literature-based evaluation of four ‘hard endpoint’ models for assessing drug-induced torsades de pointes liability. Br J Pharmacol 2008; 154: 1523-7. Wisialowski T, Crimin K, Engtrakul J, et al. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 2006; 318: 352-9. Mignot A. Clinical practices ensuring optimal quality of a thorough QT study. Life Sci Tech Bull March 2009; 22: 1-4. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011; 120: 103-10. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67: 774-6. [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] Current Drug Safety, 2012, Vol. 7, No. 2 163 Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23B-25B. Morganroth J, Brown AM, Critz S, et al. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 1993; 72: 26B-31B. Roden DM. Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. Am J Cardiol 1988; 62: 34H-38H. Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med 2009; 43: 657-62. Owens RC Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663-8. Le Berre MA, Stass H, Choudri SH, Arvis P. Relationship of plasma concentration and changes in the QTc interval in hospitalized patients receiving intravenous moxifloxacin for the treatment of community-acquired pneumonia (CAP). European Congress of Clinical Microbiology and Infectious Diseases 2007, P2069. Mason JW, Florian JA Jr, Garnett CE, Moon TE, Selness DS, Spaulding RR. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active- controlled cardiac repolarization studies. J Clin Pharmacol 2010; 50: 1249-59. Yan LK, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat 2010; 20:497- 507. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11: 52-6. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann Pharmacother 2007; 41: 336-40. Badshah A, Janjua M, Younas F, Halabi AR, Cotant JF. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug. Am J Med Sci 2009; 338: 164-6. Anonymous. Statistical Principles for Clinical Trials. Available from URL: http://www.ich.org/MediaServer.jser?@_ID=485&@_ MODE=GLB) (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) [accessed 16 Jan. 2011]. Received: March 9, 2012 Revised: May 18, 2012 Accepted: June 14, 2012